Kadmon Holdings, a New York-based developer of kinase inhibitors for autoimmune disease, fibrosis and solid tumors, was second among this year’s biggest IPO flops with negative returns of 61.3 percent. The biotech raised $75 million by offering 6.3 million shares at $12 per share in July. The company is listed on the NYSE under the symbol “KDMN”.